S&P 500 7,588.05 ▲ 34.37 (+0.46%) DOW 51,590.87 ▲ 903.80 (+1.78%) NASDAQ 26,845.01 â–ŧ 8.96 (-0.03%) US Markets Closed â€ĸ 05:31 PM ET

AZNCF

AstraZeneca PLC

Price Chart

No historical data available

Latest Quote

$187.45

+3.13 (+1.70%)
Current Price
Previous Close $184.32
Open $178.29
Day High $178.29
Day Low $178.29
Volume 200
Fetched: 2026-04-02T01:45:44
Stock Information
Quarterly Dividend / Yield $3.21 / 0.02%
Shares Outstanding 1.55B
Quarterly Dividend Yield 0.02%
Quarterly Dividend $3.21
Total Debt $32.66B
Cash Equivalents $8.18B
Revenue $58.13B
Net Income $9.40B
Sector Healthcare
Industry Drug Manufacturers - General
Market Cap $290.60B
P/E Ratio 31.09
EPS (TTM) $6.03
Exchange PNK
🌐 Visit Website
Recent Price History
No history data available. Data will be fetched automatically.
About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Period:
Loading...
Income Statement (Annual)
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
Reconciled Cost Of Revenue $10,207,000,000 $8,268,000,000 $12,391,000,000 $12,437,000,000
Cost Of Revenue $10,207,000,000 $8,268,000,000 $12,391,000,000 $12,437,000,000
Total Revenue $54,073,000,000 $45,811,000,000 $44,351,000,000 $37,417,000,000
Operating Revenue $54,073,000,000 $45,811,000,000 $44,351,000,000 $37,417,000,000
Expenses
Interest Expense $1,682,000,000 $1,589,000,000 $1,330,000,000 $1,276,000,000
Total Expenses $43,822,000,000 $37,089,000,000 $39,839,000,000 $37,556,000,000
Rent Expense Supplemental $377,000,000 $301,000,000 $268,000,000 $262,000,000
Net Non Operating Interest Income Expense $-1,337,000,000 $-1,288,000,000 $-1,249,000,000 $-1,233,000,000
Interest Expense Non Operating $1,682,000,000 $1,589,000,000 $1,330,000,000 $1,276,000,000
Operating Expense $33,615,000,000 $28,821,000,000 $27,448,000,000 $25,119,000,000
Other Operating Expenses $121,000,000 $164,000,000 $200,000,000 $308,000,000
Selling And Marketing Expense $555,000,000 $539,000,000 $536,000,000 $446,000,000
General And Administrative Expense $19,669,000,000 $17,683,000,000 $17,448,000,000 $15,144,000,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $7,035,000,000 $5,955,000,000 $3,288,000,000 $112,000,000
Net Interest Income $-1,337,000,000 $-1,288,000,000 $-1,249,000,000 $-1,233,000,000
Interest Income $345,000,000 $301,000,000 $81,000,000 $43,000,000
Normalized Income $7,158,930,000 $6,377,514,712 $3,888,210,000 $-852,710,000
Net Income From Continuing And Discontinued Operation $7,035,000,000 $5,955,000,000 $3,288,000,000 $112,000,000
Total Operating Income As Reported $10,003,000,000 $8,193,000,000 $3,757,000,000 $1,056,000,000
Net Income Common Stockholders $7,035,000,000 $5,955,000,000 $3,288,000,000 $112,000,000
Net Income $7,035,000,000 $5,955,000,000 $3,288,000,000 $112,000,000
Net Income Including Noncontrolling Interests $7,041,000,000 $5,961,000,000 $3,293,000,000 $115,000,000
Net Income Continuous Operations $7,041,000,000 $5,961,000,000 $3,293,000,000 $115,000,000
Pretax Income $8,691,000,000 $6,899,000,000 $2,501,000,000 $-265,000,000
Special Income Charges $-248,000,000 $-529,000,000 $-755,000,000 $1,195,000,000
Interest Income Non Operating $345,000,000 $301,000,000 $81,000,000 $43,000,000
Operating Income $10,251,000,000 $8,722,000,000 $4,512,000,000 $-139,000,000
Gross Profit $43,866,000,000 $37,543,000,000 $31,960,000,000 $24,980,000,000
Depreciation And Amortization In Income Statement - - - $1,000,000
Depreciation Income Statement - - - $0
Per Share
Diluted EPS $4.50 $3.81 $2.11 $0.08
Basic EPS $4.54 $3.84 $2.12 $0.08
Other
Tax Effect Of Unusual Items $-29,070,000 $-66,485,288 $-140,790,000 $226,290,000
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $15,591,000,000 $13,911,000,000 $9,826,000,000 $3,922,000,000
Total Unusual Items $-153,000,000 $-489,000,000 $-741,000,000 $1,191,000,000
Total Unusual Items Excluding Goodwill $-153,000,000 $-489,000,000 $-741,000,000 $1,191,000,000
Reconciled Depreciation $5,065,000,000 $4,934,000,000 $5,254,000,000 $4,102,000,000
EBITDA (Bullshit earnings) $15,438,000,000 $13,422,000,000 $9,085,000,000 $5,113,000,000
EBIT $10,373,000,000 $8,488,000,000 $3,831,000,000 $1,011,000,000
Diluted Average Shares $1,563,000,000 $1,562,000,000 $1,560,000,000 $1,427,000,000
Basic Average Shares $1,550,000,000 $1,549,000,000 $1,548,000,000 $1,418,000,000
Diluted NI Availto Com Stockholders $7,035,000,000 $5,955,000,000 $3,288,000,000 $112,000,000
Otherunder Preferred Stock Dividend $0 $0 $0 $0
Minority Interests $-6,000,000 $-6,000,000 $-5,000,000 $-3,000,000
Tax Provision $1,650,000,000 $938,000,000 $-792,000,000 $-380,000,000
Other Special Charges $-12,000,000 $9,000,000 $573,000,000 $-1,237,000,000
Restructuring And Mergern Acquisition $260,000,000 $520,000,000 $182,000,000 $42,000,000
Research And Development $13,583,000,000 $10,935,000,000 $9,762,000,000 $9,736,000,000
Selling General And Administration $20,224,000,000 $18,222,000,000 $17,984,000,000 $15,590,000,000
Impairment Of Capital Assets - - $0 $0
Amortization - - - $1,000,000
Fetched: 2026-02-02
Balance Sheet (Annual)
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Assets
Net Tangible Assets $-17,416,000,000 $-18,994,000,000 $-22,090,000,000 $-23,116,000,000
Total Assets $104,035,000,000 $101,119,000,000 $96,483,000,000 $105,363,000,000
Total Non Current Assets $78,208,000,000 $76,065,000,000 $73,890,000,000 $79,119,000,000
Non Current Prepaid Assets $356,000,000 $274,000,000 $243,000,000 $391,000,000
Non Current Deferred Taxes Assets $5,347,000,000 $4,718,000,000 $3,263,000,000 $4,330,000,000
Financial Assets $182,000,000 $228,000,000 $74,000,000 $102,000,000
Investmentin Financial Assets $1,632,000,000 $1,530,000,000 $1,066,000,000 $1,168,000,000
Financial Assets Designatedas Fair Value Through Profitor Loss Total $0 $0 $10,000,000 $0
Goodwill And Other Intangible Assets $58,202,000,000 $58,137,000,000 $59,127,000,000 $62,384,000,000
Other Intangible Assets $37,177,000,000 $38,089,000,000 $39,307,000,000 $42,387,000,000
Current Assets $25,827,000,000 $25,054,000,000 $22,593,000,000 $26,244,000,000
Hedging Assets Current $54,000,000 $116,000,000 $87,000,000 $83,000,000
Assets Held For Sale Current $0 $0 $150,000,000 $368,000,000
Restricted Cash $129,000,000 $102,000,000 $162,000,000 $0
Prepaid Assets $1,737,000,000 $1,617,000,000 $1,329,000,000 $1,512,000,000
Inventory $5,288,000,000 $5,424,000,000 $4,699,000,000 $8,983,000,000
Other Receivables $2,933,000,000 $2,102,000,000 $1,980,000,000 $2,101,000,000
Taxes Receivable $1,859,000,000 $1,426,000,000 $731,000,000 $663,000,000
Accounts Receivable $8,302,000,000 $8,407,000,000 $7,212,000,000 $6,031,000,000
Allowance For Doubtful Accounts Receivable $-33,000,000 $-45,000,000 $-59,000,000 $-23,000,000
Gross Accounts Receivable $8,335,000,000 $8,452,000,000 $7,271,000,000 $6,054,000,000
Cash Cash Equivalents And Short Term Investments $5,525,000,000 $5,860,000,000 $6,243,000,000 $6,398,000,000
Cash And Cash Equivalents $5,488,000,000 $5,840,000,000 $6,166,000,000 $6,329,000,000
Cash Equivalents $4,273,000,000 $4,515,000,000 $4,755,000,000 $4,868,000,000
Cash Financial $1,215,000,000 $1,325,000,000 $1,411,000,000 $1,461,000,000
Other Current Assets - - - $105,000,000
Debt
Net Debt $23,174,000,000 $21,439,000,000 $22,024,000,000 $23,372,000,000
Total Debt $30,114,000,000 $28,407,000,000 $29,143,000,000 $30,688,000,000
Long Term Debt And Capital Lease Obligation $27,619,000,000 $23,222,000,000 $23,690,000,000 $28,888,000,000
Long Term Debt $26,506,000,000 $22,365,000,000 $22,965,000,000 $28,134,000,000
Current Debt And Capital Lease Obligation $2,495,000,000 $5,185,000,000 $5,453,000,000 $1,800,000,000
Current Debt $2,156,000,000 $4,914,000,000 $5,225,000,000 $1,567,000,000
Liabilities
Total Liabilities Net Minority Interest $63,164,000,000 $61,953,000,000 $59,425,000,000 $66,076,000,000
Total Non Current Liabilities Net Minority Interest $35,298,000,000 $31,411,000,000 $33,132,000,000 $43,482,000,000
Derivative Product Liabilities $115,000,000 $38,000,000 $943,000,000 $1,583,000,000
Tradeand Other Payables Non Current $1,943,000,000 $2,617,000,000 $3,440,000,000 $3,344,000,000
Non Current Deferred Taxes Liabilities $3,305,000,000 $2,844,000,000 $2,944,000,000 $6,206,000,000
Current Liabilities $27,866,000,000 $30,542,000,000 $26,293,000,000 $22,594,000,000
Payables $8,058,000,000 $7,623,000,000 $5,841,000,000 $5,858,000,000
Other Payable $2,611,000,000 $2,280,000,000 $1,927,000,000 $1,655,000,000
Total Tax Payable $1,807,000,000 $2,076,000,000 $1,364,000,000 $1,379,000,000
Accounts Payable $3,640,000,000 $3,267,000,000 $2,550,000,000 $2,824,000,000
Equity
Common Stock Equity $40,786,000,000 $39,143,000,000 $37,037,000,000 $39,268,000,000
Total Equity Gross Minority Interest $40,871,000,000 $39,166,000,000 $37,058,000,000 $39,287,000,000
Stockholders Equity $40,786,000,000 $39,143,000,000 $37,037,000,000 $39,268,000,000
Retained Earnings $3,160,000,000 $1,502,000,000 $-574,000,000 $1,710,000,000
Long Term Equity Investment $268,000,000 $147,000,000 $76,000,000 $69,000,000
Other
Treasury Shares Number $442,342 $0 $0 $0
Ordinary Shares Number $1,550,103,897 $1,550,162,626 $1,549,800,030 $1,549,400,665
Share Issued $1,550,546,239 $1,550,162,626 $1,549,800,030 $1,549,400,665
Tangible Book Value $-17,416,000,000 $-18,994,000,000 $-22,090,000,000 $-23,116,000,000
Invested Capital $69,448,000,000 $66,422,000,000 $65,227,000,000 $68,969,000,000
Working Capital $-2,039,000,000 $-5,488,000,000 $-3,700,000,000 $3,650,000,000
Capital Lease Obligations $1,452,000,000 $1,128,000,000 $953,000,000 $987,000,000
Total Capitalization $67,292,000,000 $61,508,000,000 $60,002,000,000 $67,402,000,000
Minority Interest $85,000,000 $23,000,000 $21,000,000 $19,000,000
Additional Paid In Capital $35,379,000,000 $35,341,000,000 $35,308,000,000 $35,279,000,000
Capital Stock $388,000,000 $388,000,000 $387,000,000 $387,000,000
Common Stock $388,000,000 $388,000,000 $387,000,000 $387,000,000
Non Current Pension And Other Postretirement Benefit Plans $1,330,000,000 $1,520,000,000 $1,168,000,000 $2,454,000,000
Non Current Accrued Expenses $65,000,000 $36,000,000 $37,000,000 $25,000,000
Non Current Deferred Revenue $0 $7,000,000 $14,000,000 $26,000,000
Long Term Capital Lease Obligation $1,113,000,000 $857,000,000 $725,000,000 $754,000,000
Long Term Provisions $921,000,000 $1,127,000,000 $896,000,000 $956,000,000
Current Capital Lease Obligation $339,000,000 $271,000,000 $228,000,000 $233,000,000
Current Provisions $1,269,000,000 $1,028,000,000 $722,000,000 $768,000,000
Defined Pension Benefit $99,000,000 $92,000,000 $90,000,000 $0
Other Investments $1,632,000,000 $1,530,000,000 - -
Available For Sale Securities $1,632,000,000 $1,530,000,000 $1,056,000,000 $1,168,000,000
Goodwill $21,025,000,000 $20,048,000,000 $19,820,000,000 $19,997,000,000
Net PPE $11,647,000,000 $10,502,000,000 $9,449,000,000 $10,171,000,000
Accumulated Depreciation $-8,875,000,000 $-8,599,000,000 $-7,743,000,000 $-8,324,000,000
Gross PPE $20,522,000,000 $19,101,000,000 $17,192,000,000 $18,495,000,000
Construction In Progress $2,789,000,000 $2,045,000,000 $2,653,000,000 $2,728,000,000
Other Properties $47,000,000 $36,000,000 $32,000,000 $33,000,000
Machinery Furniture Equipment $9,518,000,000 $9,199,000,000 $7,885,000,000 $8,224,000,000
Buildings And Improvements $1,588,000,000 $1,352,000,000 $1,182,000,000 $1,133,000,000
Land And Improvements $6,580,000,000 $6,469,000,000 $5,440,000,000 $6,377,000,000
Properties $0 $0 $0 $0
Finished Goods $1,517,000,000 $1,568,000,000 $1,413,000,000 $2,012,000,000
Work In Process $2,282,000,000 $2,325,000,000 $1,864,000,000 $5,216,000,000
Raw Materials $1,489,000,000 $1,531,000,000 $1,422,000,000 $1,755,000,000
Other Short Term Investments $37,000,000 $20,000,000 $77,000,000 $69,000,000
Preferred Shares Number - - - $50,000
Fetched: 2026-02-02
Cash Flow Statement (Annual)
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Free Cash Flow
Free Cash Flow $7,275,000,000 $6,567,000,000 $7,237,000,000 $3,763,000,000
Operating Activities
Operating Cash Flow $11,861,000,000 $10,345,000,000 $9,808,000,000 $5,963,000,000
Investing Activities
Capital Expenditure $-4,586,000,000 $-3,778,000,000 $-2,571,000,000 $-2,200,000,000
Investing Cash Flow $-7,980,000,000 $-4,064,000,000 $-2,960,000,000 $-11,058,000,000
Net Other Investing Changes - $190,000,000 - $20,000,000
Financing Activities
Issuance Of Capital Stock $-43,000,000 $33,000,000 $29,000,000 $29,000,000
Financing Cash Flow $-3,996,000,000 $-6,567,000,000 $-6,823,000,000 $3,649,000,000
Net Other Financing Charges $-817,000,000 $-886,000,000 $-1,047,000,000 $-178,000,000
Cash Dividends Paid $-4,629,000,000 $-4,481,000,000 $-4,364,000,000 $-3,856,000,000
Common Stock Dividend Paid $-4,629,000,000 $-4,481,000,000 $-4,364,000,000 $-3,856,000,000
Net Common Stock Issuance $-43,000,000 $33,000,000 $29,000,000 $29,000,000
Common Stock Issuance $-43,000,000 $33,000,000 $29,000,000 $29,000,000
Other
Repayment Of Debt $-4,652,000,000 $-4,942,000,000 $-1,271,000,000 $-4,759,000,000
Issuance Of Debt $6,492,000,000 $3,816,000,000 $0 $12,929,000,000
End Cash Position $5,429,000,000 $5,637,000,000 $5,983,000,000 $6,038,000,000
Beginning Cash Position $5,637,000,000 $5,983,000,000 $6,038,000,000 $7,546,000,000
Effect Of Exchange Rate Changes $-93,000,000 $-60,000,000 $-80,000,000 $-62,000,000
Changes In Cash $-115,000,000 $-286,000,000 $25,000,000 $-1,446,000,000
Net Issuance Payments Of Debt $1,809,000,000 $-965,000,000 $-1,197,000,000 $7,894,000,000
Net Short Term Debt Issuance $-31,000,000 $161,000,000 $74,000,000 $-276,000,000
Net Long Term Debt Issuance $1,840,000,000 $-1,126,000,000 $-1,271,000,000 $8,170,000,000
Long Term Debt Payments $-4,652,000,000 $-4,942,000,000 $-1,271,000,000 $-4,759,000,000
Long Term Debt Issuance $6,492,000,000 $3,816,000,000 $0 $12,929,000,000
Interest Received Cfi $343,000,000 $287,000,000 $60,000,000 $34,000,000
Net Investment Purchase And Sale $12,000,000 $-7,000,000 $-117,000,000 $-79,000,000
Sale Of Investment $108,000,000 $129,000,000 $42,000,000 $105,000,000
Purchase Of Investment $-96,000,000 $-136,000,000 $-159,000,000 $-184,000,000
Net Business Purchase And Sale $-3,927,000,000 $-1,179,000,000 $-1,061,000,000 $-9,433,000,000
Sale Of Business $13,000,000 $0 $0 $776,000,000
Purchase Of Business $-3,940,000,000 $-1,179,000,000 $-1,061,000,000 $-10,209,000,000
Net Intangibles Purchase And Sale $-2,539,000,000 $-2,126,000,000 $-1,033,000,000 $-522,000,000
Sale Of Intangibles $123,000,000 $291,000,000 $447,000,000 $587,000,000
Purchase Of Intangibles $-2,662,000,000 $-2,417,000,000 $-1,480,000,000 $-1,109,000,000
Net PPE Purchase And Sale $-1,869,000,000 $-1,229,000,000 $-809,000,000 $-1,078,000,000
Sale Of PPE $55,000,000 $132,000,000 $282,000,000 $13,000,000
Purchase Of PPE $-1,924,000,000 $-1,361,000,000 $-1,091,000,000 $-1,091,000,000
Taxes Refund Paid $-2,750,000,000 $-2,366,000,000 $-1,623,000,000 $-1,743,000,000
Interest Paid Cfo $-1,313,000,000 $-1,081,000,000 $-849,000,000 $-721,000,000
Change In Working Capital $-893,000,000 $300,000,000 $3,757,000,000 $2,021,000,000
Change In Payable $862,000,000 $2,394,000,000 $1,165,000,000 $1,405,000,000
Change In Inventory $-131,000,000 $-669,000,000 $3,941,000,000 $1,577,000,000
Change In Receivables $-1,624,000,000 $-1,425,000,000 $-1,349,000,000 $-961,000,000
Other Non Cash Items $1,527,000,000 $1,451,000,000 $639,000,000 $1,342,000,000
Depreciation And Amortization $5,065,000,000 $4,934,000,000 $5,254,000,000 $4,102,000,000
Amortization Cash Flow $3,923,000,000 $3,926,000,000 $4,156,000,000 $3,143,000,000
Depreciation $1,142,000,000 $1,008,000,000 $1,098,000,000 $959,000,000
Gain Loss On Investment Securities $-95,000,000 $-40,000,000 $-14,000,000 $4,000,000
Net Foreign Currency Exchange Gain Loss $42,000,000 $34,000,000 $16,000,000 $20,000,000
Gain Loss On Sale Of PPE $-64,000,000 $-251,000,000 $-104,000,000 $-513,000,000
Net Income From Continuing Operations $8,691,000,000 $6,899,000,000 $2,501,000,000 $-265,000,000
Gain Loss On Sale Of Business - $0 $0 $-776,000,000
Fetched: 2026-02-02